Zobrazeno 1 - 10
of 12
pro vyhledávání: '"Nathaniel Myall"'
Autor:
Sarah Waliany, Jennifer Caswell-Jin, Fauzia Riaz, Nathaniel Myall, Han Zhu, Ronald M. Witteles, Joel W. Neal
Publikováno v:
JACC: CardioOncology. 5:85-98
Autor:
Caressa Hui, Vera Qu, Jen-Yeu Wang, Rie von Eyben, Yu-Cheng Chang, Po-Lin Chiang, Chih-Hung Liang, Jen-Tang Lu, Gordon Li, Melanie Hayden-Gephart, Heather Wakelee, Joel Neal, Kavitha Ramchandran, Millie Das, Seema Nagpal, Scott Soltys, Nathaniel Myall, Erqi Pollom
Publikováno v:
Journal of Neuro-Oncology. 160:233-240
Purpose: Although osimertinib has excellent intracranial activity in metastatic non-small cell lung cancer (NSCLC) with exon 19 deletion or L858R EGFR alterations, measures of local control of brain metastases are less well-reported. We describe lesi
Autor:
Julie Wu, Victoria Ding, Sophia Luo, Eunji Choi, Jessica Hellyer, Nathaniel Myall, Solomon Henry, Douglas Wood, Henning Stehr, Hanlee Ji, Seema Nagpal, Melanie Hayden Gephart, Heather Wakelee, Joel Neal, Summer S. Han
Publikováno v:
JCO precision oncology. 6
PURPOSE Brain metastasis is common in lung cancer, and treatment of brain metastasis can lead to significant morbidity. Although early detection of brain metastasis may improve outcomes, there are no prediction models to identify high-risk patients f
Autor:
Hyunsoo Joshua No, Neelufar Raja, Rie Von Eyben, Millie Das, Mohana Roy, Nathaniel Myall, Joel Neal, Heather Wakelee, Alexander Chin, Maximilian Diehn, Billy Wiseman Loo, Daniel Tandel Chang, Erqi Liu Pollom, Lucas Kas Vitzthum
Publikováno v:
International journal of radiation oncology, biology, physics. 114(4)
Because of the limitations of current staging systems and evolving definitions, there are limited data on oligometastatic non-small cell lung cancer (NSCLC) epidemiology. The purpose of this study was to evaluate metastatic disease burden and the inc
Autor:
Sarah Waliany, Heather Wakelee, Kavitha Ramchandran, Millie Das, Jane Huang, Nathaniel Myall, Connie Li, Judy Pagtama, Alison Holmes Tisch, Joel W. Neal
Publikováno v:
Clinical lung cancer. 23(6)
About 3%-5% of mNSCLC have ERBB2 (HER2) alterations, but currently, there are no FDA-approved targeted therapies for this indication. We compared treatment response between trastuzumab-based and non-targeted regimens in ERBB2-mutant mNSCLC.This retro
Autor:
Hui, Caressa, Qu, Vera, Wang, Jen-Yeu, von Eyben, Rie, Chang, Yu-Cheng, Chiang, Po-Lin, Liang, Chih-Hung, Lu, Jen-Tang, Li, Gordon, Hayden-Gephart, Melanie, Wakelee, Heather, Neal, Joel, Ramchandran, Kavitha, Das, Millie, Nagpal, Seema, Soltys, Scott, Myall, Nathaniel, Pollom, Erqi
Publikováno v:
Journal of Neuro-Oncology; Oct2022, Vol. 160 Issue 1, p233-240, 8p
Publikováno v:
American Journal of Clinical Oncology; Sep2022, Vol. 45 Issue 9, pS1-S63, 63p
Publikováno v:
Cancer (0008543X); Dec2021, Vol. 127 Issue 24, p4713-4723, 11p
Publikováno v:
Women's Health Weekly; 4/18/2023, p721-721, 1p
Publikováno v:
Immunotherapy Weekly; 1/31/2023, p843-843, 1p